Strata Oncology, Carbone Cancer Center integrate StrataNGS test results with Epic Genomics Module

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

FDA has approved MI Cancer Seek for use as a companion diagnostic to identify patients with cancer who may benefit from treatment with targeted therapies.

November 08, 2024

Vol.50 No.42

Drugs & Targets

NeoGenomics launches NGS assay for AML

AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia, was announced by NeoGenomics Inc.

October 11, 2024

Vol.50 No.38

Drugs & Targets

Genetics and sequencing company join to explore the UG 100TM sequencing platform to advance clinical test offerings in oncology and reproductive genomics

Myriad Genetics Inc. and Ultima Genomics Inc. join to explore Ultima’s UG 100 sequencing platform and its ppmSeq technology to advance Myriad’s ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its Lab of the Future facility in South San Francisco.

October 11, 2024

Vol.50 No.38

Drugs & Targets

Labcorp, Ultima Genomics collaborate to advance whole genome sequencing applications and oncology testing capabilities

Labcorp announced an expanded collaboration with Ultima Genomics to utilize its UG 100TM sequencing solution and ppmSeqTM technology to explore new whole genome sequencing clinical applications, including molecular residual disease in patients with early-stage solid tumor cancers.

August 02, 2024

Vol.50 No.31

Clinical Trials & Tribulations

Engineering-level molecular diagnosis: A necessity for cancer treatment—and for a successful Moonshot

The initial foray into genomic sequencing two decades ago has led to the discovery of key driver mutations and spurred drug development, thereby transforming the management of imminently lethal diseases.

Strata Oncology adds Gilead as Strata PATH Trial collaborator

Gilead Sciences, Inc. agreed to collaborate on the Strata Precision Indications for Approved THerapies (PATH) trial by providing Trodelvy (sacituzumab govitecan-hziy) for eligible patients with cancer.

January 20, 2023

Vol.49 No.03

Strata Oncology, Carbone Cancer Center integrate StrataNGS test results with Epic Genomics Module

YOU MAY BE INTERESTED IN

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

NeoGenomics launches NGS assay for AML

Genetics and sequencing company join to explore the UG 100TM sequencing platform to advance clinical test offerings in oncology and reproductive genomics

Labcorp, Ultima Genomics collaborate to advance whole genome sequencing applications and oncology testing capabilities

Engineering-level molecular diagnosis: A necessity for cancer treatment—and for a successful Moonshot

Strata Oncology adds Gilead as Strata PATH Trial collaborator

Renew today!

Subscriber content

Never miss an issue!

Login